- Home
- ALX vs ANIP Comparison
ALX vs ANIP Comparison
Compare ALX & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALX
- ANIP
- Stock Information
- Founded
- ALX 1928
- ANIP 2001
- Country
- ALX United States
- ANIP United States
- Employees
- ALX N/A
- ANIP N/A
- Industry
- ALX Real Estate Investment Trusts
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- ALX Real Estate
- ANIP Health Care
- Exchange
- ALX Nasdaq
- ANIP Nasdaq
- Market Cap
- ALX 1.2B
- ANIP 1.4B
- IPO Year
- ALX N/A
- ANIP N/A
- Fundamental
- Price
- ALX $232.05
- ANIP $66.28
- Analyst Decision
- ALX Sell
- ANIP Strong Buy
- Analyst Count
- ALX 1
- ANIP 8
- Target Price
- ALX $125.00
- ANIP $80.13
- AVG Volume (30 Days)
- ALX 78.9K
- ANIP 246.6K
- Earning Date
- ALX 08-04-2025
- ANIP 08-05-2025
- Dividend Yield
- ALX 7.80%
- ANIP N/A
- EPS Growth
- ALX N/A
- ANIP N/A
- EPS
- ALX 7.72
- ANIP N/A
- Revenue
- ALX $219,892,000.00
- ANIP $674,068,000.00
- Revenue This Year
- ALX N/A
- ANIP $30.52
- Revenue Next Year
- ALX N/A
- ANIP $7.40
- P/E Ratio
- ALX $30.16
- ANIP N/A
- Revenue Growth
- ALX N/A
- ANIP 30.27
- 52 Week Low
- ALX $184.76
- ANIP $52.50
- 52 Week High
- ALX $251.63
- ANIP $77.00
- Technical
- Relative Strength Index (RSI)
- ALX 59.34
- ANIP 58.88
- Support Level
- ALX $229.99
- ANIP $63.17
- Resistance Level
- ALX $234.70
- ANIP $66.18
- Average True Range (ATR)
- ALX 5.00
- ANIP 1.77
- MACD
- ALX 0.30
- ANIP 0.07
- Stochastic Oscillator
- ALX 85.96
- ANIP 75.27
About ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.